• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dominari Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    12/12/25 5:19:12 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOMH alert in real time by email
    false 0000012239 0000012239 2025-12-10 2025-12-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT 

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 12, 2025 (December 10, 2025)

     

    Dominari Holdings Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41845   52-0849320

    (State or other Jurisdiction

    of incorporation)

      (Commission File Number)  

    (IRS Employer

    Identification No.)

     

    725 5th Avenue, 22nd Floor

    New York, NY 10022

    (Address of principal executive offices) (Zip Code)

     

    (212) 393-4540

    Registrant’s telephone number, including area code 

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   DOMH   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    On December 10, 2025, at the annual meeting of stockholders (the “Annual Meeting”) of the Company, of the Company’s (i) 15,998,027 shares of common stock, each having one vote per share of common stock, (ii) 3,825 shares of Series D Convertible Preferred Stock, each having 0.007285 votes per share of Series D Convertible Preferred Stock, and (iii) 834 shares of Series D-1 Convertible Preferred Stock, each having 0.007285 votes per share of Series D-1 Convertible Preferred Stock, issued and outstanding and eligible to vote as of the record date of October 13, 2025, a quorum of 7,349,686 voting shares, or approximately 45.94% of the eligible shares of voting stock entitled to vote at the Annual Meeting, was present or represented by proxy. Each of the matters set forth below is described in detail in the proxy statement (the “Proxy Statement”) filed with the Securities and Exchange Commission on November 10, 2025. The following actions were taken at the Annual Meeting:

     

    Proposal 1: Election of Class II Directors

     

    The first proposal was the election of one (1) Class II director to serve for a three-year term that expires at the 2028 annual meeting of stockholders and until the election and qualification of their respective successors in office, subject to their earlier death, resignation, or removal. The vote on the proposal was as follows:

     

    Name of Nominee  FOR  WITHHELD  BROKER
    NON-VOTE
    Anthony Hayes  4,902,235  167,155  2,280,296

     

    The nominee was elected.

     

    Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm

     

    The second proposal was the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2025. The vote on the proposal was as follows:

     

    FOR  AGAINST  ABSTAIN
    6,626,234  643,461  79,991

     

    Proposal 2 was approved by a majority of the votes cast.

     

    Proposal 3: Approval of Increase in Reserved Shares of Common Stock Under the Company’s 2022 Equity Incentive Plan

     

    The third proposal was the approval of an amendment to Section 4(a) of the Company’s 2022 Equity Incentive Plan (the “2022 Plan”) to increase the number of shares of common stock reserved for issuance with respect to awards granted under the 2022 Plan from 11,404,404 shares of common stock to 11,720,750 shares of common stock. The vote on the proposal was as follows:

    FOR  AGAINST  ABSTAIN  BROKER
    NON-VOTE
    4,618,923  434,746  15,721  2,280,296

     

    Proposal 3 was approved by a majority of the votes cast.

     

    1

     

    Proposal 4: Approval of the Potential Issuance of Shares of Common Stock in excess of 19.99% of the Company’s Outstanding Common Stock or Voting Power

     

    The fourth proposal was the approval of, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of shares of common stock (or securities exercisable for shares of common stock), in one or more non-public financing transactions, in an aggregate amount exceeding 19.99% of the Company’s outstanding common stock or voting power, at a price that may be below the Minimum Price (as defined in the Nasdaq rules) pursuant to the issuance of shares of common stock (or securities exercisable for common stock) pursuant to those certain Advisory Agreements, as amended, with the Company’s Board of Advisors. The vote on the proposal was as follows:

     

    FOR  AGAINST  ABSTAIN  BROKER
    NON-VOTE
    4,647,510  407,751  14,129  2,280,296

     

    Proposal 4 was approved by a majority of the votes cast. 

     

    Proposal 5: Approval of Renewal of the Rights Agreement

     

    The fifth proposal was the approval of the renewal of the Rights Agreement, dated as of October 11, 2023, by and between the Company and Continental Stock Transfer & Trust Company and extend the rights granted under Section 7(a) of the Rights Agreement through October 11, 2026. The vote on the proposal was as follows:

     

    FOR  AGAINST  ABSTAIN  BROKER
    NON-VOTE
    4,920,813  128,737  19,840  2,280,296

     

    Proposal 5 was approved by a majority of the votes cast. 

     

    2

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: December 12, 2025

     

    DOMINARI HOLDINGS INC.  
         
    By: /s/ Anthony Hayes  
    Name: Anthony Hayes  
    Title: Chief Executive Officer  

     

     

    3

     

    Get the next $DOMH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOMH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DOMH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that, following its press release issued on December 11, 2025, the board of directors has updated the record date and payment date for the previously announced special cash dividend of approximately $10 million, or approximately $0.44 per share. The dividend is now payable on or about January 26, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on January 5, 2026. For additional informatio

    12/12/25 5:45:00 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces $10 Million Cash Dividend

    NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $10 million, or approximately $0.44 per share.  The dividend is payable on or about January 23, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on December 31, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/ About Dominari Ho

    12/11/25 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO Devall Christopher Franklin was granted 10,000 shares, increasing direct ownership by 7% to 155,702 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/12/25 9:48:09 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Wool Kyle Michael decreased direct ownership by 1% to 2,453,817 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 7:54:17 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    SEC Filings

    View All

    Dominari Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    12/12/25 5:19:12 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form RW filed by Dominari Holdings Inc.

    RW - Dominari Holdings Inc. (0000012239) (Filer)

    11/12/25 8:00:13 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Dominari Holdings Inc.

    DEF 14A - Dominari Holdings Inc. (0000012239) (Filer)

    11/10/25 8:08:01 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Leadership Updates

    Live Leadership Updates

    View All

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board

    Accomplished entrepreneur and global speaker to strengthen firm's marketing, investor engagement and strategic communications to help drive growth NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced the appointment of Brian Parsley to its Board of Directors. Parsley, an accomplished entrepreneur, behavioral analyst and internationally recognized speaker, will support the firm's growth by enhancing its marketing, investor outreach and overall communications strategy. Mr. Parsley has more than 30 years of experience in entrepreneurship,

    9/10/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that, following its press release issued on December 11, 2025, the board of directors has updated the record date and payment date for the previously announced special cash dividend of approximately $10 million, or approximately $0.44 per share. The dividend is now payable on or about January 26, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on January 5, 2026. For additional informatio

    12/12/25 5:45:00 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces $10 Million Cash Dividend

    NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $10 million, or approximately $0.44 per share.  The dividend is payable on or about January 23, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on December 31, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/ About Dominari Ho

    12/11/25 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari 2025 Revenue Surges 703% in First Nine Months, Balance Sheet Strengthens Significantly

    Q3 Revenue of $50.8 Million, up 49% from Q2, 2025 NEW YORK, Nov. 11, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company"), today announced highlights of its financial results for the quarter ended September 30, 2025, which were filed today with the Securities and Exchange Commission ("SEC") in the Company's quarterly SEC Form 10Q. "We achieved remarkable year-to-date revenue growth in the third quarter of more than 700% year-over-year, reflecting strong underwriting activity, robust client engagement and disciplined operational execution," sa

    11/11/25 8:00:00 AM ET
    $ABTC
    $DOMH
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 8:56:04 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 4:32:07 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care